Premium
Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR
Author(s) -
Murugesan G.,
GuentherJohnson J.,
Mularo F.,
Cook J. R.,
Daly T. M.
Publication year - 2016
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.12484
Subject(s) - microbiology and biotechnology , biology , mutation , cold pcr , exon , myelofibrosis , genetics , essential thrombocythemia , indel , bone marrow , gene , point mutation , polycythemia vera , genotype , single nucleotide polymorphism , immunology
Summary Introduction The 2008 WHO criteria for the diagnosis and classification of myeloproliferative neoplasms ( MPN ) rely in part upon the assessment of mutations in JAK 2 and MPL genes. Recently, mutations in calreticulin ( CALR ) have been identified in MPN lacking JAK 2 and MPL mutations. We have validated a sensitive fragment analysis assay to detect CALR mutations. Methods Genomic DNA from peripheral blood, bone marrow, and FFPE bone marrow clot preparations from 52 MPN specimens with known JAK 2 and MPL mutation status and 29 non‐ MPN specimens was analyzed. CALR mutation testing was performed by fragment length analysis, and the results were confirmed by sequencing. Accuracy, precision, sensitivity, specificity, and robustness of the assay were determined. Results Forty specimens (32 JAK 2+, 2 JAK 2 ‐/ MPL +, and 6 JAK 2 ‐/ MPL ‐) were negative for CALR mutations. Twelve specimens had CALR mutations including 52 bp deletion (5), 5 bp insertion (6), and a novel 9 bp deletion (1). This 9 bp inframe deletion occurring at an allelic burden of 50% would delete three amino acids. One specimen with a 52 bp deletion also had JAK 2 V617F mutation. All 29 non‐ MPN specimens were negative for CALR mutations. The assay accurately identified the mutation status of all 52 MPN specimens and had a coefficient of variation <3% for the fragment size and mutant peaks with a sensitivity of 5% for indels. Conclusions Fragment analysis is an accurate and sensitive method for the detection of CALR indels. The novel 9 bp deletion is likely a germline variant. Consequence of coexisting JAK 2 V617F and CALR mutations requires careful interpretation.